Bronchopulmonary Dysplasia Pipeline 2025: Revolutionizing Neonatal Lung Care 

DelveInsight's "Bronchopulmonary Dysplasia Pipeline Insight 2025" report delivers in-depth analysis on over 10 companies and more than 12 pipeline drugs shaping the Bronchopulmonary Dysplasia treatment landscape. It includes detailed profiles of Bronchopulmonary Dysplasia pipeline drugs, spanning clinical and nonclinical development stages. Additionally, it evaluates Bronchopulmonary Dysplasia pipeline therapies by product category, development phase, administration method, and molecular structure. It also outlines discontinued pipeline products in this field.

Discover our cutting-edge advancements in Bronchopulmonary Dysplasia studies. Get more details on our pioneering pipeline now! @ Bronchopulmonary Dysplasia Pipeline Outlook

Key Highlights from the Bronchopulmonary Dysplasia Pipeline Report

• On August 27, 2025, OHB Neonatology Ltd. revealed a trial aimed at assessing whether an experimental medication can avert Bronchopulmonary Dysplasia, alleviating the impact of persistent lung conditions in very preterm newborns, in contrast to those under routine neonatal care.

• DelveInsight's Bronchopulmonary Dysplasia pipeline report illustrates a vibrant arena with over 10 active participants advancing more than 12 pipeline treatments for Bronchopulmonary Dysplasia management.

• The prominent Bronchopulmonary Dysplasia Companies include Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc., and others.

• Promising Bronchopulmonary Dysplasia Pipeline Therapies include Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem®, Curosurf, OHB-607, Infasurf, Palivizumab, and others.

Access for updates and join the transformation in Respiratory Health Care @ Bronchopulmonary Dysplasia Clinical Trials Assessment

Bronchopulmonary Dysplasia Emerging Drugs Profile

• AT-100: Airway Therapeutics, Inc Zelpultide alfa, or AT-100, is an innovative biologic created by Airway Therapeutics, Inc. It represents a recombinant form of human surfactant protein D (rhSP-D), designed to curb inflammation and infection while adjusting immune responses. This candidate focuses on bronchopulmonary dysplasia (BPD). The medication is currently in Phase III development for Bronchopulmonary Dysplasia treatment.

• OHB-607: Oak Hill Bio OHB-607, formerly referred to as TAK-607, is a groundbreaking treatment developed by Oak Hill Bio to tackle major health issues in extremely preterm babies. This investigational agent is a recombinant form of insulin-like growth factor 1 (IGF-1), paired with its binding protein IGFBP-3. It targets the prevention of bronchopulmonary dysplasia (BPD). OHB-607 seeks to normalize IGF-1 levels to match those in full-term pregnancies, aiding the proper maturation of essential organs such as the lungs, brain, and eyes. The drug is presently in Phase II development for Bronchopulmonary Dysplasia therapy.

The Bronchopulmonary Dysplasia Pipeline Report offers insights into

• The report furnishes comprehensive details on organizations developing treatments for Bronchopulmonary Dysplasia, including the total therapies each company is advancing.

• It examines various therapeutic candidates divided into initial, intermediate, and advanced development phases for Bronchopulmonary Dysplasia care.

• Bronchopulmonary Dysplasia Companies are engaged in precision therapy development, with active and dormant (inactive or halted) initiatives.

• Bronchopulmonary Dysplasia Drugs in progress, categorized by development stage, delivery route, target receptor, standalone or combined treatment, distinct action mechanisms, and molecular class.

• In-depth review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Bronchopulmonary Dysplasia sector.

Explore more on Bronchopulmonary Dysplasia drug prospects in our innovative research and development efforts @ Bronchopulmonary Dysplasia Unmet Needs

Bronchopulmonary Dysplasia Companies Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc., and others.

Bronchopulmonary Dysplasia pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Bronchopulmonary Dysplasia Products are classified by various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Keep up with our progress in reshaping Respiratory Disease management @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives

Scope of the Bronchopulmonary Dysplasia Pipeline Report

• Coverage- Global

• Bronchopulmonary Dysplasia Companies- Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc., and others.

• Bronchopulmonary Dysplasia Pipeline Therapies- Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem®, Curosurf, OHB-607, Infasurf, Palivizumab, and others.

• Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For an extensive summary of our recent findings and upcoming strategies, review the complete Bronchopulmonary Dysplasia Pipeline details on our site @ Bronchopulmonary Dysplasia Emerging Drugs and Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Bronchopulmonary Dysplasia: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Bronchopulmonary Dysplasia- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. AT-100: Airway Therapeutics, Inc

9. Mid Stage Products (Phase II)

10. OHB-607: Oak Hill Bio

11. Early Stage Products (Phase I)

12. Drug Name: Company Name

13. Preclinical and Discovery Stage Products

14. Drug name: Company name

15. Inactive Products

16. Bronchopulmonary Dysplasia Key Companies

17. Bronchopulmonary Dysplasia Key Products

18. Bronchopulmonary Dysplasia- Unmet Needs

19. Bronchopulmonary Dysplasia- Market Drivers and Barriers

20. Bronchopulmonary Dysplasia- Future Perspectives and Conclusion

21. Bronchopulmonary Dysplasia Analyst Views

22. Bronchopulmonary Dysplasia Key Companies

23. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us 

Kanishk

kkumar@delveinsight.com